MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? by Caruso, S. et al.
REVIEW
MicroRNAs in colorectal cancer stem cells: new regulators
of cancer stemness?
S Caruso1,3, V Bazan1,3, C Rolfo2, L Insalaco1, D Fanale1, G Bronte1, LR Corsini1, S Rizzo1, G Cicero1 and A Russo1
Recently, the hypothesis that colorectal tumors originate from a subpopulation of cells called ‘cancer stem cells’ (CSCs) or
tumor-initiating cells, which exhibit stem-like features, has been conﬁrmed experimentally in various human cancers. Several
studies have conﬁrmed the existence of colorectal CSCs (CRCSCs) and have demonstrated that this rare cell population can be
isolated by the expression of speciﬁc cell surface biomarkers. MicroRNAs (miRNAs) are a class of small non-coding RNAs, which are
crucial for post-transcriptional regulation of gene expression and participate in a wide variety of biological functions, including
development, cell proliferation, differentiation, metabolism and signal transduction. Moreover, new evidences suggest that miRNAs
could contribute to preserve stemness of embryonic stem cells and could be involved in maintaining stemness of CSCs. Recent
studies have begun to outline the role of miRNAs in regulation of CRCSCs. This review aims to summarize the recent advancement
about the roles of miRNAs in CRCSCs that may represent a step forward in understanding the molecular mechanisms and the
possible approaches for colorectal cancer therapy.
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INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer
worldwide that causes 655 000 deaths per year. In 2011, CRC will
account forB141 000 new cases and 49 000 deaths in the United
States, making it the second leading cause of death from cancer.1
Although early detection methods and therapeutic approaches
have been studied to prolong patient survival in recent years,
surgical resection is the most successful treatment. It is possible
that microscopic neoplastic foci could remain after the surgical
treatment and subsequently metastatic diseases could develop.2
CRC is a heterogeneous tumor and the existence of therapy-
resistant cancer cell populations can negatively affect adjuvant
therapies, such as radiotherapy and chemotherapy.3
With regard to pathogenesis and molecular events, CRC is one
of the best-characterized cancers. The accumulation of mutations
involving oncogenes, tumor suppressor genes (gatekeepers) and
repair/stability genes (caretakers) determines the development
and progression from adenoma to cancer and metastatic disease.
At the DNA level, these alterations are cumulative and include
before adenomatous polyposis coli (APC) or b-catenin mutations
and then mutation of other genes, such as K-Ras, p53 and
transforming growth factor-b (TGF-b), in the context of a growing
genomic instability.3
In recent years, the cancer stem cell (CSC) model has been
suggested to explain the functional heterogeneity and the
carcinogenesis process of cancer (Figure 1). According to CSC
hypothesis, a small fraction of cancer cells, which exhibit stem-like
features, both self-renewal and pluripotency, have the ability of
initiating and sustaining tumor growth, metastasis and resistance
to therapy.4 CSCs, also called tumor-initiating cells, were ﬁrst
identiﬁed in hematologic malignancies and more recently
in several solid tumors, such as CRC.5,6
MicroRNAs (miRNAs) are a recently discovered class of
small non-coding RNA molecules. Mature miRNA can regulate
gene expression by binding to 30 untranslated regions of the
complementary mRNA. This interaction triggers mRNA degrada-
tion or inhibition of protein synthesis.7 During the last decade, it
has become clear that alterations in the expression of several
miRNAs are extensively associated with the etiology and clinical
outcome of many human cancers, including CRC, suggesting
potential roles in carcinogenesis.8
Recent ﬁndings suggest that miRNAs could be involved in
maintaining stemness of colon CSCs, though the role of miRNAs
in human colorectal CSCs (CRCSCs) remains poorly understood.
CRC STEM CELLS
Stem cells are unspecialized cells that are in general deﬁned by
two functional properties: the ability to self-renew for a long
period of time and the potential to differentiate into other mature
cells of the tissue of origin (multipotency).5,6,9
Intestinal stem cell population resides at the base of the colonic
crypt and gives rise to the three major cell lineages, namely
colonocytes, the primary absorptive cell; goblet cells, the mucin-
secreting cell; enteroendocrine cells, the hormone-producing
population endocrine.9
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The concept that tumors contain heterogeneous cell popula-
tions with diverse biological characteristics and potentials has
long been recognized. The traditional model of tumorigenesis
suggests that this heterogeneity can be explained by genetic
aberrations and microenvironmental inﬂuence, making each
tumor cell capable of initiation and propagation.10
Recently, the ‘cancer stem cell’ theory of carcinogenesis has
proposed that within the tumor mass there is a predetermined cell
population with a ‘stem cell’ phenotype, able to perpetuate the
cancer, whereas the rest of the neoplastic cells are unable of
self-renewal.6 This suggests that tumors may arise and grow due
to CSC formation, which could be an endless reserve to tumor
progression and subsistence (Figure 1).
Although increasing evidence supports the existence of the
CSCs, the source of these cells remains unclear. In fact, it has not
been recognized unequivocally that CSCs originate from normal
stem cells, but also genetic or epigenetic changes may confer
stem-like ability on a progenitor or differentiated cell.11 In this
context, miRNAs may have a key role. Evidence that miRNAs are
involved in stem cell fate is provided by the fact that the absence
of DGCR8, an RNA-binding protein essential for miRNA biogenesis,
in knockout embryonic stem cells is responsible for slow
proliferation rates and defective differentiation.12
It has long been accepted the existence of CRCSCs in human
CRC13–15 and the potential role of CRCSCs to tumor progression,
metastasis and therapeutic failure.
According to the CSC model, it has been proposed that the ﬁrst
mutation occurs in a colonic stem cell located at the crypt bottom
that in the course of his long life can accumulate oncogenic
mutations (Figure 1). Although the concept that CRC develops as a
result of a sequence of mutations occurring during the clonal
expansion of a single stem cell has been widely accepted, the
existence of CRCSCs had not been experimentally demonstrated
until recently due to difﬁculties in identifying a speciﬁc biomarker
for this rare cell population. In the past few years, new evidences
have supported the existence of CRCSCs, conﬁrming that
the neoplastic cell population of CRC can be isolated by the
expression of speciﬁc cell surface biomarkers.3
Recently, experiments using a combination of ﬂow cytometry to
identify a ‘putative’ stem cell population and xenograft models
involving immunodeﬁcient mice to determine their tumor-
initiating potential have assessed the expression of speciﬁc CRCSC
biomarkers.16
In the ﬁrst two studies, CD133, also known as Prominin-1, was
used to identify the tumorigenic cell population within CRC.13,15
O’Brien et al.13 isolated CD133þ cells from both primary and
metastatic human CRCs and injected the sorted cells in the renal
capsule of nonobese diabetic/severe combined immunodeﬁciency
(NOD/SCID) mice. CD133þ cells readily developed tumors in mice,
whereas the CD133 cell population was unable to generate
tumors even after serial transplantation in mice. Moreover, tumor
xenografts generated by CD133þ cells displayed the same tumor
phenotype of the parental tumor and were reproducibly
maintained upon serial transplantation.
Similary, in the second study, Ricci-Vitiani et al. showed that
CD133þ cells, accounting for B2.5% of tumor cells, could be
maintained in vitro as colon ‘tumor spheres’ for 41 year, without
losing their in vivo tumorigenic potential.15
Both studies demonstrated the expression of CD133 also in
normal colon tissue, although at lower frequency, reinforcing
the hypothesis that CD133þ cells in cancer samples might result
from oncogenic transformation of normal colonic stem cells.
Subsequently, the cell adhesion molecule CD44 and the
epithelial surface antigen (EpCAM) were proposed as alternative
markers for CRCSC isolation, with further enrichment by CD166.
Subcutaneous injection of puriﬁed CD44þ /EpCAMhigh cells into
NOD/SCID mice resulted in high-frequency generation of tumor
xenograft, whereas CD44 /EpCAMlow cells did not have this
ability. Moreover, when CD44þ /EpCAMhigh are used together with
the mesenchymal stem cell marker CD166 was possible to observe
an increase in the success of tumor xenograft.14
In a more recent study, the detoxifying enzyme aldehyde
dehydrogenase 1 (ALDH1) has been proposed as a promising new
marker for normal and malignant human colonic stem cells.
As few as 25 ALDH1þ cancer cells, isolated by ﬂow cytometry,
were able to generate tumor xenografts in NOD/SCID mice.
Notably, a subsequent isolation of cancer cells using a second
marker (CD44 or CD133 serially) increased modestly tumor-
initiating ability, implying that ALDH1 can be used as another
putative CRCSC marker17
In addition to CD133, CD166, CD44, EpCAM and ALDH1, a
potential CRCSC marker, is proposed to be the somatic intestinal
stem/progenitor cell marker Lgr5 (leucine-rich repeat-containing
G-protein-coupled receptor 5). The Lgr5 expression is variable
among CRC cases, correlated signiﬁcantly with lymphatic and
vascular invasion, lymph node metastasis and tumor stage,
suggesting the involvement of this marker in tumor progression.18
The isolation of CRCSC is a very important step to understand
the molecular pathways activated or expressed only in CSC or to
discover the molecular mechanisms underlying the regulation
of these cells, as miRNAs.
SIGNALING PATHWAYS IN CRC AND CSCs
The homeostatic self-renewal of the intestine depends on a
complex network of evolutionary highly conserved signaling
pathways that control many cellular processes, including
proliferation, differentiation, migration and cell death.
Figure 1. Cancer stem cell model. The development of various
tissues is supported by stem cells. These cells, in the physiological
context, proliferate, become progenitor cells, and finally acquire a
differentiated phenotype. In the course of life, at the level of stem
cells can accumulate oncogenic mutations and genetic aberration
that give rise to CSCs. CSCs are defined by characteristics similar to
those of normal stem cells, mainly their abilities to self-renew, a
characteristic that leads to tumor development.
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In CRC, the alteration of these signaling pathways, such as Wnt/
b-catenin, Notch, TGF-b, bone morphogenetic proteins (BMPs) and
Hedgehog (SHH), is closely related to disrupted stem cell self-
renewal and differentiation.
It has long been accepted that the canonical Wnt pathway is an
important regulator of normal intestinal stem cells and more
recently has been proposed a role in CRCSCs regulation.19,20
The role of Wnt pathway in CRC has been highlighted by
the discovery of mutations in the APC gene as the cause of
familial adenomatous polyposis, which is a hereditary cancer
predisposition syndrome.21 Experiments on knockout mice have
shown that Wnt signaling is involved in endoderm formation and
also exerts fundamental role in crypt development, maintenance
and proliferation.22 Moreover, Wnt signaling is involved in the
process of epithelial to mesenchymal transition.10
Notch is another important pathway involved in the regulation
of intestinal stem cells and the activation of Notch signaling
inhibits differentiation and stimulates progenitor proliferation.23
A recent study on CRC cell lines suggested that Notch knockdown
reduced proliferation, increased apoptosis and decreased
clonogenicity, whereas overexpression of Notch had the
opposite effect.24 In addiction, inhibition of Notch signaling in
APC/multiple intestinal neoplasia (APCmin) mice reduce cancer
proliferation, inhibit CSC self-renewal and increase differention to
goblet cells.25 Furthermore, Notch pathway is able to interact with
Wnt signaling through a not entirely clear mechanism.26 The
interaction between the Notch and Wnt signaling pathways and
the role of Notch in the inhibition of differentiation suggest
that Notch could be involved in the regulation of CSCs.
The TGF-b signaling pathway has an important role in intestinal
stem cell function and carcinogenesis because it is involved in the
regulation of several biologic processes, such as cell proliferation,
differentiation, migration and apoptosis, and for these reasons
it is one of the most commonly altered pathways in human
cancers.27,28 Recently, it has been suggested that TGF-b signaling
is involved in gut endoderm development and the transition of
stem cells to a more differentiated phenotype.29 Several authors
also suggest that the TGF-b and Wnt pathways synergistically
promote CRC tumorigenesis, conﬁrming that disruption of both
signaling pathways cooperate to drive tumor initiation, likely in
colonic stem cells.30–33
BMPs are a subgroup of TGF-b superfamily members that are
involved in controlling intestinal differentiation. In particular, it has
been reported that BMP4 promotes terminal differentiation,
apoptosis and chemosensitization of CRCSCs, highlighting the
potential role of disrupted BMP4 signaling in CRC.34 Finally, the
role of Hedgehog in CRC remains controversial but appears to be
essential for human colon cancer growth, recurrence, metastases
and stem cell expansion,35 probably acting by Wnt suppressor.36
MICRORNAs IN CRCSCs
miRNAs are a class of endogenous, small (18–25 nucleotide
in length), single-stranded non-coding RNAs that regulate
gene expression at post-trascriptional level by acting on speciﬁc
messenger targets, inducing mRNA degradation or translational
arrest. In short, miRNAs biogenesis begins with primary miRNAs,
inactive forms that are transcribed by RNA polymerase II or
excised as introns portions.37–39 The primary miRNAs are
processed in the nucleus by the ribonuclease Drosha and the
resultant precursor miRNA (pre-miR) is then exported to the
cytoplasm where the ribonuclease Dicer processes it again to form
the active miRNA. miRNA is now transferred to the Argonauta
protein that is located within the RNA-induced silencing complex
(RISC). The miRNA RISC can now interact with the complementary
mRNA to repress their translation.37–39 Interestingly, a single
miRNA can regulate many mRNAs and a single mRNA can be
the target of several miRNAs. MiRNAs are involved in several
biological functions, including development, cell proliferation,
differentiation, metabolism and signal transduction. Recent
studies have shown that abnormal patterns of miRNAs are
present in human cancers, suggesting potential role in
carcinogenesis.7,8,40
In 2003, Michael et al.41 reported for the ﬁrst time the miRNAs
alteration in CRC, showing the downregulation of miR-143 and
miR-145 in CRC tumor tissues compared with normal tissues. Over
the years, several studies have shown miRNAs that are extensively
Table 1. microRNAs involved in colorectal cancer
Downregulated Upregulated
let-7 let-7g
let-7a-1 miR-10a
let-7b miR-15b
let-7g miR-16
miR-1 miR-17
miR-9-3 miR-17-5p
miR-10b miR-18a
miR-16 miR-19a
miR-23b miR-19b
miR-24 miR-20
miR-26a miR-20a
miR-30a-3p miR-21
miR-30a-5p miR-21*
miR-30c miR-23a
miR-101 miR-25
miR-102 miR-27a
miR-125a miR-27b
miR-132 miR-29a
miR-133a miR-29b
miR-133b miR-30c
miR-138 miR-30e
miR-139 miR-31
miR-143 miR-34a
miR-145 miR-92
miR-181a miR-92a
miR-181b miR-93
miR-192 miR-93-1
miR-195 miR-95
miR-200b miR-96
miR-210 miR-106a
miR-215 miR-106b,
miR-218 miR-107
miR-224 miR-124b
miR-296 miR-125a
miR-320 miR-130b
miR-372 miR-132
miR-378* miR-133a
miR-455 miR-135b
miR-484 miR-141
miR-422a, miR-147
miR-422b miR-151
miR-497 miR-152
miR-181b
miR-182
miR-183
miR-185
miR-191
miR-195
miR-199a
miR-200c
miR-203
miR-221
miR-224
miR-339
miR-510
miR-513
miRNAs with conflicting expression levels in the two groups are underlined
and in bold.
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deregulated in CRC, as summarized in Table 1.41–49 Moreover,
other studies have reported that there are different miRNA proﬁles
in each tumor subtype, depending on tumor location and
mutation status of p53 and K-Ras.49
To date, numerous studies have described the role of miRNAs in
normal stem cells of many tissues, whereas only few studies are
available on the function of miRNAs in CSCs. Recently, several
authors have begun to outline the role of miRNAs in regulation of
CRCSCs. The ﬁrst evidence showed that miR-17-92 cluster and its
target, E2F1, exhibit a similar expression pattern in developing
embryonic tissue and adult CRC. Furthermore, inhibition of miR-
17-5p, a member of the miR-17-92 cluster, decreased DLD1 cancer
cell proliferation and clonogenicity. In situ hybridization showed
highest expression of miR-17-5p in the crypt progenitor compart-
ment, which suggests that it is a factor involved in stem cells
regulation.50 Song et al.51,52 in two different studies emphasized
the miR-140 and miR-215 involvement in CRCSCs. They showed
that the overexpression of miR-140 and mir-215 can inhibit CRC
cell proliferation and cause cell cycle arrest. CRC stem-like cells,
expressing CD133high and CD44high, also showed increased miR-
140 and miR-215 expression levels by four- and three–fold,
respectively, compared with control parental CRC cells. In 2010,
Zhang et al.53 reported a different miRNAs expression proﬁle in
human colonic adenocarcinoma cell line HT-29 selected by CD133
positivity and high expression of stemness genes, such as Wnt,
BMI1, Notch1 and OCT3/4. Moreover, these cells were able to form
tumor spheres in vitro and tumors in BALB/c nude female mice.
The authors identiﬁed, through microarray analysis, 19
differentially expressed miRNAs in CD133þ CRCSCs compared
with CD133 population, 11 miRNAs were found upregulated,
including miR-16-2*, miR-105, miR-155, miR-181b, miR-185, miR-
423-5p, miR-455-3p, miR-455-5p, miR-494, miR-744, miR-1826 and
8 miRNAs were downregulated, including miR-31, miR-151-3p,
miR-151-5p, miR-221, miR-320d, miR-429, miR-548d-5p and
miR-636.53 Some of these, such as miR-429 and miR-155 are
involved in CSC differentiation and epithelial–mesenchymal
transition.54,55 Birtarte et al.56 performed miRNA proﬁling in
colonspheres with properties of CSCs obtained from different
colon cancer cell lines and showed that miR-451 was abundantly
downregulated. Ectopic expression of miR-451 caused a decrease
in self-renewal, tumorigenicity and chemoresistance to irinotecan
in colonspheres. They identiﬁed cyclooxygenase-2 as an indirect
miR-451 target gene involved in CSC growth. MiR-451 targets
macrophage migration inhibitory factor (MIF) gene, involved in the
expression of cyclooxygenase-2 that allows Wnt activation, which
is essential for CSC growth.56 Another study reported that HCT-116
and HT-29, CSCs-enriched cell lines, show from three- to seven-
fold overexpression of miR-21. MiR-21 upregulation induces an
increase of b-catenin levels, TCF/LEF activity and the expression of
c-Myc, cyclin-D, which are also increased in CSCs and causes a
decrease of TGFbR2, which is involved in differentiation. For this
reason, the authors reported that miR-21 can have an important
role in regulating stemness by modulating TGFbR2 signaling in
CRC cells.57 Additional miRNA proﬁling in colon CSC lines,
SW1116csc, has resulted in 46 differentially expressed miRNAs.
The miR-93 expression level was the lowest in SW1116csc
compared with differentiated colon cancer cells. Overexpression
of miR-93 consistently inhibited cell proliferation and colony
formation of colon CSCs by targeting histone deacetylase 8 and
the transducin-like enhancer of Split (TLE4), which inhibit Wnt/b-
catenin signaling pathway.58
Recently, Zhu et al.59 demonstrated that Achaete scute-like 2
(Ascl2) is involved in maintenance of cancer progenitor cells. Ascl2
blockade in HT-29 cells signiﬁcantly reduced the expression levels
of stemness-associated genes, such as CD133, Lgr5, Oct4, Bmi1,
Sox2 and C-myc and led to signiﬁcant inhibition of tumorsphere
formation compared with control. Furthermore, the authors
identiﬁed 84 differentially expressed miRNAs in shRNA-Ascl2/HT-
29 cells compared with shRNA-control/HT-29 cells, using
microarray analysis. Among these, miRNA-17, miRNA-20a and
miRNA-302b were signiﬁcantly downregulated, whereas, let-7b,
miRNA-124, miRNA-125b were signiﬁcantly upregulated but only
miR-302b mimic restored the tumor spheres formation and the
self-renewal of shRNA-Ascl2/HT-29, increasing Ascl2 mRNA and
protein levels.59 In 2012, Xu et al.60 reported that the side
population cells sorted from CRC possess CSC-like properties,
such as self-renewal, differentiation, resistance to chemotherapy,
invasive and strong tumor formation ability. Microarray analysis
shows that miR-328 was signiﬁcantly downregulated in side
population cells and for this reason can represent a potential
stemness miRNA with an important role in maintaining cancer
stem-like phenotype. Table 2 summarizes all the miRNAs that have
been found deregulated in CRCSCs.
Analysis of several online databases (Tarbase, miRBase, miro`)
indicates that these miRNAs not directly interact with mRNAs of
human stemness genes, such as Wnt/b-catenin, NOTCH1, TGF-b
and Hedgehog. However, the studies reported above suggest that
miRNAs involved in CRCSCs may interact with signaling pathways,
mediated by these genes, that regulate the stem cells.
THERAPEUTIC IMPLICATIONS
Recent evidence suggests that miRNAs may represent potential
new therapeutic approaches in cancer treatment. Moreover,
Table 2. Summary of potential deregulated miRNAs in CRCSCs
Downregulated Upregulated Studies
miR-17-5p Monzo et al.50
miR-140 Song et al.51
miR-215 Song et al.52
miR-31, miR-151-3p, miR-151-5p, miR-221, miR-320d,
miR-429, miR-548d-5p, miR-636
miR-16-2*, miR-105, miR-155, miR-181b, miR-185, miR-423-5p,
miR-455-3p, miR-455-5p, miR-494, miR-744, miR-1826
Zhang et al.53
miR-451 Bitarte et al.56
miR-21 Yu et al.57
miR-93, miR-1231, miRPlus-F1080, miR-524-3p, miR-886-3p,
miR-561, miR-497, miR-23a, miR-886-5p, miRPlus-A1087,
miRPlus-E1170
miRPlus-E1102, miR-138-2, miR-31, miR-17, miR-374a, miR-424,
miRPlus-F1181, miRPlus-E1238, miR-542-3p, miR-582-3p, miR-584,
miR-522, miR-590-5p, miR-487b, miR-29c, miR-96, miR-193a-3p,
miR-20a, miR-301a, miRPlus-E1106, miR-30e, miR-874, miR-19a,
miR-519a, miRPlus-A1065, miR-521, miR-876-5p, miR-493, miR-
101, miR-32, miR-33a, miR-194, miR-215, miR-29b, miR-192
Yu et al.58
miR-302b Zhu et al.59
miR-328 Xu et al.60
MiRNAs that are also deregulated in CRC are identified in bold.
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CSC research and the increasing evidences that many cancer types,
such as CRC, have their origin in CSC population provide novel
approaches that could be used speciﬁcally for cancers with
resistance to current therapies.61 Despite this, today we know
very little about therapeutic implications of miRNAs in CRCSCs. To
date, only two studies have shown that miRNAs contribute to
CRCSC therapeutic resistance by modulating CRCSC-speciﬁc
signaling pathways. In 2009, Song et al.51 reported that miR-140
confer a methotrexate and 5-ﬂuoroucil-resistant phenotype in
CD133þhigh CD44
þ
high colon cancer cells by inhibiting cell proliferation
by targeting histone deacetylase 4. In 2010, the same authors
showed that miRNA-215 enhances the chemoresistance of
CD133þhigh CD44
þ
high colon cancer cells to methotrexate and
Tomudex by inhibiting cell proliferation and inducing G2-arrest
through the suppression of DTL expression.52 Taken together, these
studies suggest that some miRNAs may have a key role in the
mechanism of tumor chemoresistence.
CONCLUSIONS
In summary, increasing evidence suggests that CSCs or tumor-
initiating cells cause tumor establishment, progression, metastasis
and therapeutic failure. However, the role of miRNAs in human
CRCSCs remains poorly understood. Recently, several research
groups have begun to outline the role of miRNAs in the
maintenance of stemness of CRCSCs. These studies suggest that
some miRNAs can have a key role in the regulation of CRCSCs by
interacting, directly or indirectly, on signaling pathways implicated
in cancer stemness. Nevertheless to date, there is little information
about the differences that exist between normal colorectal stem
cell and CRCSCs, concerning miRNAs expression.
The identiﬁcation of miRNAs involved in CRCSCs may represent
a step forward in understanding the molecular mechanisms and
characterization of CRCSCs and simultaneously may be useful to
develop therapeutic approaches that speciﬁcally target this rare
population of cells.
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